Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 27, 2012First European Implants of INGENIO™ MRI Pacemaker with New Image Ready™ Technology Performed This Week
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its INGENIO™ and ADVANTIO™ pacemakers in patients in need of a magnetic resonance imaging (MRI) scan. Now...
-
Jul 2, 2012S-ICD® System selected as most innovative in the field of Electrophysiology and Cardiac Techniques
Attendees of Cardiostim 2012, a global medical conference held recently in Nice, France, have selected the S-ICD® System recently acquired by Boston Scientific Corporation (NYSE: BSX) as the most...
-
Jul 2, 2012Milestone Marks Next Step Toward FDA Submission for Stroke Reduction Device for Patients with Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the PREVAIL confirmatory study, designed to gain U.S. Food and Drug Administration (FDA) approval for the WATCHMAN® Left...
-
Jun 14, 2012Boston Scientific Announces First Patient Active with LATITUDE™ NXT Remote Patient Management SystemNext-generation wireless remote patient management system enabled for INGENIO™ family of pacemakers is now in use in Europe
Boston Scientific Corporation (NYSE: BSX) has initiated use of the LATITUDE NXT Remote Patient Management System with patients in Europe. Dr. Roberto Verlato, head of cardiology at Camposampiero...
-
Jun 8, 2012Adds First and Only Commercially Available Subcutaneous ICD Technology that Offers New Life-Saving Therapy Option to Patients at Risk of Sudden Cardiac Arrest
Boston Scientific Corporation (NYSE: BSX) has closed its acquisition of Cameron Health, Inc. of San Clemente, California, and, as a result, added to its product portfolio the world's first and...
-
May 23, 2012
Boston Scientific Corporation (NYSE: BSX) annuncia i risultati a due anni dello studio PLATINUM Small Vessel, i quali dimostrano eccellenti risultati in termini di sicurezza ed efficacia per il...
-
May 21, 2012Zweijahresdaten belegen für den 2,25 mm Platin Chrom Stent PROMUS Element von Boston Scientific geringe Raten an unerwünschten Ereignissen wie Myokardinfarkt oder Stentthrombose
Die Boston Scientific Corporation (NYSE: BSX) hat heute die Zweijahres-Ergebnisse seiner PLATINUM Small Vessel Studie bekanntgegeben. Die Ergebnisse belegen für das Everolimus freisetzende 2,25...
-
May 18, 2012Two-year Clinical Data Demonstrate Low Adverse Event Rates, Including No Myocardial Infarction or Stent Thrombosis, for the Boston Scientific 2.25 mm PROMUS Element Platinum Chromium Stent
Boston Scientific Corporation (NYSE: BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS...
-
May 16, 2012I risultati dello studio REPRISE I suggeriscono che il dispositivo riduce al minimo il rigurgito aortico
Boston Scientific Corporation (NYSE: BSX) annuncia i risultati dello studio di fattibilità REPRISE I, che ha valutato la sicurezza in acuto del sistema Lotus™ per la valvola aortica in pazienti...
-
May 16, 2012Die Resultate der REPRISE-I-Studie legen nahe, dass das Aortenklappen-System die paravalvulaere Regurgitation minimiert
Boston Scientific Corporation (NYSE: BSX) hat die Ergebnisse der Projektstudie REPRISE I bekannt gegeben, in der die Sicherheit des Aortenklappen-Systems Lotus™ für Patienten mit schwerer...